EurekaMag.com logo
+ Site Statistics
References:
53,214,146
Abstracts:
29,074,682
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Electrophysiologic effects of cibenzoline in humans related to dose and plasma concentration


American Heart Journal 112(2): 333-339
Electrophysiologic effects of cibenzoline in humans related to dose and plasma concentration
The electrophysiologic effects of a new antiarrhythmic agent, cibenzoline, were investigated in 25 patients with an average age of 62 years. The compound was administered intravenously, as a bolus given over 2 minutes, then as a slow infusion over 40 minutes. Each subject was randomly allocated to receive one of the following four doses: 1.55 mg/kg (six patients), 1.8 mg/kg (six patients), 2.2 mg/kg (six patients), or 2.6 mg/kg (seven patients). Plasma cibenzoline concentrations at these doses were 378 .+-. 80, 525 .+-. 194, 618 .+-. 72, and 731 .+-. 196 ng/ml, respectively. Administration of 1.55 mg/kg cibenzoline significantly shortened the sinus cycle (60 msec on average; p < 0.025) and increased intraatrial (+8 msec; p < 0.05) and His-Purkinje conduction times (HV interval +13 msec; p < 0.001). At 1.80 mg/kg, prolongation occurred in the HV interval (+9 msec; p < 0.02), the duration of the QRS complex (+20 msec; p > 0.05), and the QT interval (+18 msec; p < 0.025). At the higher doses these changes became more marked (maximum increase: HV = +16 msec, p < 0.001; QRS + 25msec; p < 0.001; QT + 26 msec, p < 0.05), and additional effects on atrioventricular nodal conduction time (AH interval + 17 msec; p < 0.05) and atrial (+20 msec; p < 0.05) and ventricular (+10 msec; p > 0.05) effective refractory periods were observed. Prolongation of the QRS duration was the effect that correlated best with plasma cibenzoline levels (r = 0.47; p < 0.05). These results allow an understanding of the antiarrhythmic activity of cibenzoline in humans.

Accession: 005349291

PMID: 3526853

DOI: 10.1016/0002-8703(86)90271-1

Download PDF Full Text: Electrophysiologic effects of cibenzoline in humans related to dose and plasma concentration



Related references

The electrophysiological effects of intravenous cibenzoline in man with reference to dose and plasma concentration. American Heart Association Monograph: Iii-166, 1985

Cardiac electrophysiological effects of cibenzoline in the conscious dog: plasma concentration-response relationships. Journal of Cardiovascular Pharmacology 14(4): 616-621, 1989

D sotalol electrophysiologic properties in relation to dose and to plasma concentration. American Heart Association Monograph (114): III-169, 1985

Cardiovascular beta-adrenergic blocking effects of bornaprolol in humans: relation to dose and plasma concentration. Journal of Cardiovascular Pharmacology 9(6): 694-698, 1987

The electrophysiologic effects of oral cibenzoline. Journal of Electrocardiology 17(1): 15-23, 1984

Cibenzoline electrophysiologic effects in patients with supraventricular tachycardia. European Heart Journal 10(ABSTR SUPPL): 302, 1989

Electrophysiologic effects of intravenous cibenzoline in idiopathic atrial flutter in man. European Heart Journal 12(ABSTR SUPPL): 337, 1991

Electrophysiologic effects and efficacy of cibenzoline in patients with supraventricular tachycardia. Journal of Cardiovascular Pharmacology 20(3): 375-379, 1992

Electrophysiologic effects of intravenous cibenzoline succinate, a new class I antiarrhythmic agent. Kokyu to Junkan. Respiration & Circulation 36(10): 1119-1124, 1988

Electrophysiologic effects of cibenzoline in wpw syndrome and atrioventricular nodal reentrant tachycardia. Zeitschrift fuer Kardiologie 78(10): 640-646, 1989